EMA Authorised: Sorafenib Accord (sorafenib tosilate) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Sorafenib Accord (sorafenib tosylate) for hepatocellular carcinoma and renal cell carcinoma. Accord Healthcare S.L.U. is the marketing author…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib Accord (sorafenib tosylate)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Hepatocellular;Carcinoma, Renal Cell. MAH: Accord Healthcare S.L.U.. Decision date: 09/04/2026